This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (179)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Quality of Care  • Evidence-Based Medicine  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

A Meta-analysis

Sonal Singh, MD; Yoon K. Loke, MBBS, MD; Curt D. Furberg, MD, PhD

JAMA. 2007;298:1189-1195.

Context  Recent reports of serious adverse events with rosiglitazone use have raised questions about whether the evidence of harm justifies its use for treatment of type 2 diabetes.

Objective  To systematically review the long-term cardiovascular risks of rosiglitazone, including myocardial infarction, heart failure, and cardiovascular mortality.

Data Sources  We searched MEDLINE, the GlaxoSmithKline clinical trials register, the US Food and Drug Administration Web site, and product information sheets for randomized controlled trials, systematic reviews, and meta-analyses published in English through May 2007.

Study Selection  Studies were selected for inclusion if they were randomized controlled trials of rosiglitazone for prevention or treatment of type 2 diabetes, had at least 12 months of follow-up, and monitored cardiovascular adverse events and provided numerical data on all adverse events. Four studies were included after detailed screening of 140 trials for cardiovascular events.

Data Extraction  Relative risks (RRs) of myocardial infarction, heart failure, and cardiovascular mortality were estimated using a fixed-effects meta-analysis of 4 randomized controlled trials (n = 14 291, including 6421 receiving rosiglitazone and 7870 receiving control therapy, with a duration of follow-up of 1-4 years).

Results  Rosiglitazone significantly increased the risk of myocardial infarction (n = 94/6421 vs 83/7870; RR, 1.42; 95% confidence interval [CI], 1.06-1.91; P = .02) and heart failure (n = 102/6421 vs 62/7870; RR, 2.09; 95% CI, 1.52-2.88; P < .001) without a significant increase in risk of cardiovascular mortality (n = 59/6421 vs 72/7870; RR, 0.90; 95% CI, 0.63-1.26; P = .53). There was no evidence of substantial heterogeneity among the trials for these end points (I² = 0% for myocardial infarction, 18% for heart failure, and 0% for cardiovascular mortality).

Conclusion  Among patients with impaired glucose tolerance or type 2 diabetes, rosiglitazone use for at least 12 months is associated with a significantly increased risk of myocardial infarction and heart failure, without a significantly increased risk of cardiovascular mortality.

Author Affiliations: Department of Medicine (Dr Singh) and Division of Public Health Sciences (Dr Furberg), Wake Forest University School of Medicine, Winston-Salem, North Carolina; and School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, England (Dr Loke).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials
, , , and
JAMA. ;298():1180-1188.
FULL TEXT  

Cardiovascular Risk and the Thiazolidinediones: Deja Vu All Over Again?
and
JAMA. ;298():1216-1218.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No
Kassem and Raz
Diabetes Care 2009;32:S337-S341.
FULL TEXT  

Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature
Potenza et al.
Am. J. Physiol. Endocrinol. Metab. 2009;297:E685-E694.
ABSTRACT | FULL TEXT  

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
Juurlink et al.
BMJ 2009;339:b2942-b2942.
ABSTRACT | FULL TEXT  

Review article: Thiazolidinediones and heart failure
Chaggar et al.
Diabetes and Vascular Disease Research 2009;6:146-152.
ABSTRACT  

A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
The BARI 2D Study Group
NEJM 2009;360:2503-2515.
ABSTRACT | FULL TEXT  

Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).
Lonn et al.
J Am Coll Cardiol 2009;53:2028-2035.
ABSTRACT | FULL TEXT  

A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study)
Takagi et al.
J Am Coll Cardiol Intv 2009;2:524-531.
ABSTRACT | FULL TEXT  

A call for more transparency of registered clinical trials on endometriosis
Guo et al.
Hum Reprod 2009;24:1247-1254.
ABSTRACT | FULL TEXT  

Glucose Control and Vascular Complications in Type 2 Diabetes
Banarer et al.
NEJM 2009;360:2031-2032.
FULL TEXT  

Implications of recent clinical trials on pay-for-performance
Gellad et al.
Am J Health Syst Pharm 2009;66:864-867.
FULL TEXT  

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Response to Cobitz and Ambery
Nathan and for the American Diabetes Association and European
Diabetes Care 2009;32:e59-e59.
FULL TEXT  

Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus
van der Meer et al.
Circulation 2009;119:2069-2077.
ABSTRACT | FULL TEXT  

Peroxisome Proliferator-Activated Receptor {gamma} Activation Restores Islet Function in Diabetic Mice through Reduction of Endoplasmic Reticulum Stress and Maintenance of Euchromatin Structure
Evans-Molina et al.
Mol. Cell. Biol. 2009;29:2053-2067.
ABSTRACT | FULL TEXT  

Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients
Vanasse et al.
Diabetes and Vascular Disease Research 2009;6:87-93.
ABSTRACT  

The Benefit and Risk of Antidiabetic Agents Used in Patients With Heart Disease
Cheng et al.
Journal of Pharmacy Practice 2009;22:179-193.
ABSTRACT  

Review: Durable glycaemia -- the promised land
Campbell
British Journal of Diabetes & Vascular Disease 2009;9:53-63.
ABSTRACT  

Management of type 2 diabetes and lipids: a critique of the NICE guidelines 2008
Song and Gray
British Journal of Diabetes & Vascular Disease 2009;9:69-74.
ABSTRACT  

Heart Failure as a Multiple Hormonal Deficiency Syndrome
Sacca
Circ Heart Fail 2009;2:151-156.
FULL TEXT  

Coronary circulatory function abnormalities in insulin resistance insights from positron emission tomography.
Schelbert
J Am Coll Cardiol 2009;53:S3-S8.
ABSTRACT | FULL TEXT  

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke et al.
CMAJ 2009;180:32-39.
ABSTRACT | FULL TEXT  

Thiazolidinediones: Do harms outweigh benefits?
Lipscombe
CMAJ 2009;180:16-17.
FULL TEXT  

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
Nathan et al.
Clin. Diabetes 2009;27:4-16.
FULL TEXT  

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
Nathan et al.
Diabetes Spectr. 2009;22:6-17.
FULL TEXT  

Thiazolidinediones and cardiovascular outcomes in type 2 diabetes
Singh and Furberg
Heart 2009;95:1-3.
FULL TEXT  

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
Nathan et al.
Diabetes Care 2009;32:193-203.
ABSTRACT | FULL TEXT  

Intensive glucose control did not prevent important complications in type 2 diabetes
Montori and Malaga
Evid. Based Med. 2008;13:168-169.
FULL TEXT  

Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy
Winkelmayer et al.
Arch Intern Med 2008;168:2368-2375.
ABSTRACT | FULL TEXT  

Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis
Pinelli et al.
The Annals of Pharmacotherapy 2008;42:1541-1551.
ABSTRACT | FULL TEXT  

Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review
Selvin et al.
Arch Intern Med 2008;168:2070-2080.
ABSTRACT | FULL TEXT  

Intensive Glucose Control in Type 2 Diabetes
Jenny-Avital et al.
NEJM 2008;359:1519-1521.
FULL TEXT  

Rosiglitazone and pioglitazone in the treatment of diabetes mellitus
Odom et al.
Am J Health Syst Pharm 2008;65:1846-1850.
FULL TEXT  

Rosiglitazone Treatment Reduces Diabetic Neuropathy in Streptozotocin-Treated DBA/2J Mice
Wiggin et al.
Endocrinology 2008;149:4928-4937.
ABSTRACT | FULL TEXT  

Thiazolidinediones in Type 2 Diabetes: A Cardiology Perspective
Khanderia et al.
The Annals of Pharmacotherapy 2008;42:1466-1474.
ABSTRACT | FULL TEXT  

The Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-{alpha}-Dependent Manner In Vitro and In Vivo in Mice
Orasanu et al.
J Am Coll Cardiol 2008;52:869-881.
ABSTRACT | FULL TEXT  

Pharmacological Differences of Glitazones: Does Peroxisome Proliferator-Activated Receptor-{alpha} Activation Make the Difference?
Kintscher
J Am Coll Cardiol 2008;52:882-884.
FULL TEXT  

Obese Mice Lacking Inducible Nitric Oxide Synthase Are Sensitized to the Metabolic Actions of Peroxisome Proliferator-Activated Receptor-{gamma} Agonism
Dallaire et al.
Diabetes 2008;57:1999-2011.
ABSTRACT | FULL TEXT  

Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes
Triplitt and Alvarez
Diabetes Spectr. 2008;21:177-189.
ABSTRACT | FULL TEXT  

Treating Elderly People with Diabetes and Stages 3 and 4 Chronic Kidney Disease
Abaterusso et al.
CJASN 2008;3:1185-1194.
ABSTRACT | FULL TEXT  

Patient-Important Outcomes in Registered Diabetes Trials
Gandhi et al.
JAMA 2008;299:2543-2549.
ABSTRACT | FULL TEXT  

Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force
Norris et al.
ANN INTERN MED 2008;148:855-868.
ABSTRACT | FULL TEXT  

Regulation of Macrophage Functions by PPAR-{alpha}, PPAR-{gamma}, and LXRs in Mice and Men
Rigamonti et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:1050-1059.
ABSTRACT | FULL TEXT  

Induction of CXCR2 Receptor by Peroxisome Proliferator-Activated Receptor {gamma} in Human Macrophages
Rigamonti et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:932-939.
ABSTRACT | FULL TEXT  

Diabetic retinopathy and risk of heart failure.
Cheung et al.
J Am Coll Cardiol 2008;51:1573-1578.
ABSTRACT | FULL TEXT  

PROactive: time for a critical appraisal
Betteridge et al.
Eur Heart J 2008;29:969-983.
ABSTRACT | FULL TEXT  

Glitazones in type 2 diabetes: an update
DTB 2008;46:25-29.
ABSTRACT | FULL TEXT  

Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone
Dahabreh
Clin Trials 2008;5:116-120.
ABSTRACT  

The year in atherothrombosis.
Sanz et al.
J Am Coll Cardiol 2008;51:944-955.
FULL TEXT  

The importance of treating cardiometabolic risk factors in patients with type 2 diabetes
Barnett
Diabetes and Vascular Disease Research 2008;5:9-14.
ABSTRACT  

Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein
Dandona
Mayo Clin Proc. 2008;83:333-342.
ABSTRACT | FULL TEXT  

Peroxisome Proliferator-Activated Receptor-{gamma}-Mediated Effects in the Vasculature
Duan et al.
Circ. Res. 2008;102:283-294.
ABSTRACT | FULL TEXT  

Management of Type 2 Diabetes -- Polling Results
Halperin et al.
NEJM 2008;358:e8-e8.
FULL TEXT  

Projecting future drug expenditures--2008
Hoffman et al.
Am J Health Syst Pharm 2008;65:234-253.
ABSTRACT | FULL TEXT  

New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond
Inzucchi and McGuire
Circulation 2008;117:574-584.
ABSTRACT | FULL TEXT  

New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications
McGuire and Inzucchi
Circulation 2008;117:440-449.
FULL TEXT  

Glucose-lowering therapy after myocardial infarction: more questions than answers
Radke and Schunkert
Eur Heart J 2008;29:141-143.
FULL TEXT  

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: Update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
Nathan et al.
Diabetes Care 2008;31:173-175.
FULL TEXT  

Standards of Medical Care in Diabetes--2008
American Diabetes Association
Diabetes Care 2008;31:S12-S54.
FULL TEXT  

Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes
Lipscombe et al.
JAMA 2007;298:2634-2643.
ABSTRACT | FULL TEXT  

Vascular disease in paediatric type 2 diabetes: the state of the art
Vaughan et al.
Diabetes and Vascular Disease Research 2007;4:297-304.
ABSTRACT  

A Crash Course in Stats
Kirkman
DOC News 2007;4:2-2.
FULL TEXT  

Thiazolidinediones and Increased MI Risk: A Class Effect?
Journal Watch Cardiology 2007;2007:3-3.
FULL TEXT  

Cardiovascular Risk and the Thiazolidinediones: Deja Vu All Over Again?
Solomon and Winkelmayer
JAMA 2007;298:1216-1218.
FULL TEXT  

Thiazolidinediones and Heart Disease Risk
JWatch General 2007;2007:2-2.
FULL TEXT